"The study adds to growing evidence that dupilumab, while highly effective for managing atopic dermatitis, may also be linked ...

CSPC Pharmaceutical Group ( ($HK:1093) ) has issued an update. CSPC Pharmaceutical Group has announced that its Dupilumab Injection, a biosimilar ...

For nearly a decade, 71-year-old Ho Thian Kong struggled with the effects of chronic rhinosinusitis with nasal polyps, a ...

For severe chronic rhinosinusitis with nasal polyps, novel stapokibart reduced symptoms and polyp size atop treatment with a ...

Dupixent shows potential as a treatment for atopic dermatitis, alopecia and vitiligo, targeting shared immune pathways for ...

Dupilumab may provide a nonsteroidal option for managing cancer therapy-related skin toxicities, according to a study.

Phase 1 healthy volunteer data surpassing Kymera's target product profile, and further validating its oral, dupilumab-like profile KT-621 BroADen Phase 1b trial in ...

Phase 1 healthy volunteer data surpassing Kymera’s target product profile, and further validating its oral, dupilumab-like profile ...

A new international study led by researchers at McMaster University has identified the most effective and safest treatments ...